DRD1 and Parkinson disease: We found that in parkinsonian mice, therapeutic doses of dopamine D2/3 receptor (D2/3R) or D1 receptor (D1R) agonists drove more pronounced delay discounting, reminiscent of what has been reported in PD/ICD patients on medication.